Retatrutide in 2026 Q2: what changed

The second quarter of 2026 was the busiest three months retatrutide has had. Its first Phase 3 obesity trial closed in April, Eli Lilly put out topline numbers in May, and the first peer reviewed Phase 3 paper reached The Lancet in June. Across the same weeks the FDA published warning letters to two firms selling the compound as a research chemical^[1]. None of it moved the legal position. As The Pharmaceutical Journal put it while reporting the trial, "retatrutide remains investigational and unlicensed"^[4].

April: the obesity trial finished

TRIUMPH-1 is the trial the whole obesity case for retatrutide rests on, and its registry record quietly ticked over during the quarter. ClinicalTrials.gov lists NCT05929066 with 2,335 participants enrolled, a primary completion date of 6 April 2026, a study completion date of 30 April 2026, and a status of completed^[3]. Before April the obesity evidence was a Phase 2 paper and a lot of forecasting. After April there was a finished Phase 3 dataset, even if nobody outside Lilly had seen it yet.

May: the 28.3 percent topline

Lilly released the headline results on 21 May 2026, and the reported figures depend on who wrote them up. The Cleveland Clinic Journal of Medicine, covering the data as presented, gives mean weight loss at 80 weeks of 28.3% (70.3 lb) on 12 mg, 25.9% (64.4 lb) on 9 mg and 19.0% (47.2 lb) on 4 mg^[7]. The Pharmaceutical Journal, writing on 22 May, reported a lower set for the same doses: 25.0%, 23.7% and 17.6%, against 3.9% on placebo, plus up to 30% at week 104 in participants with a baseline BMI of 35 or above who escalated to their maximum tolerated dose^[4]. Either way these are the largest numbers any drug in the GLP-1 family has posted in a completed Phase 3 obesity trial, and the gap between the two write-ups is the sort of thing a peer reviewed paper settles and a press release does not.

The tolerability line deserves equal billing. Discontinuation because of adverse events ran at 11.3% on 12 mg versus 4.9% on placebo, with 4.1% on 4 mg and 6.9% on 9 mg. At the top dose, 42.4% reported nausea, 32.0% diarrhoea and 25.3% vomiting^[4]. Weight loss at this scale is not free, and the dose that produced the headline is also the dose people left.

The UK Science Media Centre published independent reaction the same day. Graham Finlayson, chair in psychobiology at the University of Leeds, put the result next to surgery, while Marie Spreckley of the MRC Epidemiology Unit at Cambridge said that "if confirmed in the full peer-reviewed publication, this would represent one of the largest weight reductions reported for a pharmacological obesity treatment". Simon Cork of Anglia Ruskin University called the findings "incredibly promising". All three made the same caveat: these were company released topline figures, not a manuscript with methods, adherence data or subgroup breakdowns^[5].

These topline results suggest that retatrutide may produce weight losses approaching the range historically associated with bariatric surgery, which is striking.

June: the first Phase 3 paper is about diabetes

The peer reviewed milestone arrived in a different indication. TRANSCEND-T2D-1 went online in The Lancet on 6 June 2026 and into print on 13 June (volume 407, pages 2402 to 2413). It randomised 537 adults with type 2 diabetes at 48 sites in the United States, Mexico and India to weekly retatrutide at 4 mg, 9 mg or 12 mg, or placebo, for 40 weeks. HbA1c fell by 1.69 to 1.94 percentage points from a 7.9% baseline, against 0.81 on placebo, and body weight fell by 11.5% to 15.3%, against 2.6%^[6].

Safety in the paper reads better than the obesity topline. Gastrointestinal events were the most common and were described as generally mild to moderate, subsiding over time. No severe hypoglycaemia was recorded in any arm. Discontinuation for adverse events was 2% to 5% on retatrutide and 0% on placebo^[6]. Both datasets were presented at the American Diabetes Association meeting on 6 June, TRANSCEND-T2D-1 by Harpreet Bajaj and TRIUMPH-1 by Ania Jastreboff^[7]. For context on how the class stacks up, our pages on tirzepatide and semaglutide carry the comparable trial numbers.

What the FDA did about the sellers

On 7 April 2026 the agency posted two warning letters dated 31 March. Gram Peptides was told that its "Retatrutide" and "Tirzepatide" listings are unapproved new drugs, and that selling bacteriostatic water alongside them shows the products were intended for injection into people^[1]. Prime Sciences of Scottsdale was cited over a catalogue coded as GLP1-R (retatrutide), GLP1-S (semaglutide) and GLP1-T (tirzepatide), labelled for "laboratory research purposes only" while the site quoted human trial weight-loss figures^[2].

The research-use-only label is the part readers should take from this. The FDA's standing page on unapproved GLP-1 drugs names retatrutide among the substances "illegally sold" with that disclaimer and then shipped to consumers with dosing instructions^[8]. A vial bought that way has no approved application behind it, and the grey market risks are the same ones we have documented all year.

What did not change in Q2

The approval position held all quarter. Nothing from the FDA, nothing from the EMA, nothing from the MHRA, and nothing from any national agency we cover. A completed trial is not a marketing authorisation, which is why The Pharmaceutical Journal still described the drug in May as investigational and unlicensed^[4].

The durability question is also untouched. The longest retatrutide data point in the public record is 104 weeks in a subgroup, and there is no published outcome trial showing what happens to heart attacks, strokes or kidney function. Anyone comparing these figures to bariatric surgery is comparing two years of drug data against decades of surgical follow-up. If you are weighing a GLP-1 option now, the approved ones are semaglutide and tirzepatide, and that conversation belongs with a clinician who knows your history.